US biotech Oblenio Bio raises US$62m Series B for an autoimmune T-cell engager optioned from China's Leads Biolabs Pfizer Ventures leads with Deep Track, GV and Aditum; the asset LBL-051 comes from Nanjing's Leads Biolabs, another China-discovered drug advanced through a US company Whose Money ·5 takes ·Jul 2